IP Verse

Pharmaceutical Formulations

Patent No. EP4233846 (titled "Pharmaceutical Formulations") was filed by Gilead Sciences on Jun 29, 2016. The application was issued on Dec 4, 2024.

Patent Summary

A pharmaceutical tablet for treating viral infections, such as HIV-1, comprises only two active ingredients: tenofovir alafenamide (TAF) or its pharmaceutically acceptable salt, and emtricitabine (FTC) or its pharmaceutically acceptable salt. The TAF component provides the equivalent of 25 mg of TAF free base and constitutes 7-9% by weight of the tablet. The FTC component provides the equivalent of 200 mg of FTC free base. The formulation is designed for stability, minimizing TAF degradation products (e.g., PMPA) despite the presence of FTC. The tablet may be a coated, immediate-release monolayer form, potentially comprising microcrystalline cellulose, croscarmellose sodium, and magnesium stearate, while remaining substantially free of rilpivirine, lactose, and starch.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ELKINGTON AND FIFESep 4, 2025ELKINGTON AND FIFE
EIPSep 3, 2025EIP
HAMM&WITTKOPP PATENTANWÄLTE PARTMBBSep 2, 2025HAMM&WITTKOPP PATENTANWÄLTE PARTMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4233846

GILEAD SCIENCES
Application Number
EP23162978A
Filing Date
Jun 29, 2016
Status
Granted And Under Opposition
Nov 1, 2024
Publication Date
Dec 4, 2024
External Links
Slate, Register , Google Patents